You are here: Home » Companies » Results
Business Standard

Torrent Pharma Q2 net up 27% despite dip in US and Brazil revenues

Firm's consolidated total revenue for the quarter, however, fell marginally by 0.7% to stand at Rs 2,023 crore

Topics
Torrent Pharma | Q2 results | United States

Vinay Umarji  |  Ahmedabad 

medicine, drugs, pharma
In the US market, Torrent Pharma's sales continued to be impacted by price erosion on base portfolio and absence of new launches.

Despite a dip in its US and revenues, Torrent Pharmaceuticals Ltd. has posted a 27 per cent growth in its consolidated profit after tax (PAT) for the second quarter ended September 30, 2020 for the current financial year 2020-21. The company registered a net profit of Rs 310 crore for Q2 of fiscal year 2020-21 as compared to Rs 244 crore in the said quarter last year.

The company's consolidated total revenue for the quarter ended September 30, 2020, however, fell marginally by 0.7 per cent to stand at Rs 2023 crore, as against Rs 2039 crore in Q2 of FY'2019-20.

In terms of geographies, Torrent Pharma's India revenues grew marginally by seven per cent during the quarter to stand at Rs 963 crore as compared to one per cent growth clocked by the Indian Pharmaceutical Market (IPM), the company stated quoting AIOCD data. On the other hand, the company's US and revenues fell by 14 per cent and 18 per cent to stand at Rs 327 crore and Rs 129 crore during the second quarter, respectively.

According to Torrent Pharma, the company's sub-chronic and acute segments witnessed gradual recovery during the quarter while chronic momentum continued even as its field force productivity for the quarter was Rs 8 lakhs with an MR strength of 4,000.

ALSO READ: Delhi High Court defers hearing in petitions against NAA to December 7

In the US market, Torrent Pharma's sales continued to be impacted by price erosion on base portfolio and absence of new launches. As on September 30, 2020, the company had 47 abbreviated new drug applications (ANDAs) pending approval and six tentative approvals received with one ANDA being filed during the second quarter.

On the other hand, the company stated that with unlocking of the economy, also witnessed gradual recovery during the quarter with Torrent’s performance being aided by its chronic portfolio and market share gain.

Torrent Pharma's Germany revenues were up by four per cent at Rs 261 crore during Q2 of FY'21 with the company largely completing upgradation of its quality management systems.

Meanwhile, the company's spend during the quarter ended September 30, 2020 stood at Rs 119 crore or six per cent of revenues as against Rs 130 crore in the corresponding period last year.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, October 26 2020. 19:27 IST
RECOMMENDED FOR YOU
.